AbbVie sidelines CytomX after seeing midphase oncology ADC data, opens talks on returning...

cafead

Administrator
Staff member
  • cafead   Mar 28, 2023 at 10:32: AM
via AbbVie has ditched its pact with CytomX Therapeutics. After seeing 83% of patients in the latest data cut develop anemia, the Big Pharma has dropped the cancer program for strategic portfolio reasons—and begun negotiating to sell the lead antibody-drug conjugate (ADC) back to CytomX.

article source